Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
ID: 357136Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity aimed at developing novel theories and methods for understanding the genetic architecture of complex human traits through the R21 Exploratory/Developmental Research Grant mechanism. This initiative seeks interdisciplinary applications that address the interplay of genetic and non-genetic factors influencing trait variation, emphasizing the use of large-scale datasets and innovative approaches from various scientific fields. The grant allows for a maximum budget of $275,000 over two years, with a prohibition on clinical trials and a limit on new data generation to 20% of project costs. Interested applicants should note that proposals are due by January 7, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a funding opportunity to develop new theories and methods for understanding the genetic architecture of complex human traits, under the R21 Exploratory/Developmental Research Grant mechanism. The initiative is designed to address gaps in current research methodologies, aiming to incorporate a broader understanding of both genetic and non-genetic factors influencing trait variation. Applications are encouraged from interdisciplinary teams combining expertise in genetics, biology, sociology, and other fields, emphasizing the need for novel approaches that utilize large-scale datasets. The funding opportunity allows a maximum budget of $275,000 over two years, prohibiting clinical trials and limiting new data generation to 20% of project costs. Key submission dates begin in early 2025, with an expiration date of January 8, 2027. Proposals must demonstrate rigor, originality, and relevance to human health, ensuring ethical implications are considered, particularly concerning sensitive traits. The review process will assess scientific merit, feasibility, and investigator expertise through peer reviews and council evaluations, ultimately determining funding based on scientific impact and availability of resources. This initiative underlines NIH's commitment to advancing genomic medicine and enhancing public health outcomes through innovative research.
    Similar Opportunities
    Loading similar opportunities...